Pura Vida Investments LLC Has $402,000 Stake in Natera, Inc. $NTRA

Key Points

• Pura Vida Investments LLC cut its Natera stake by 99.0% in the third quarter to 2,500 shares valued at $402,000, representing about 2.6% of its portfolio and its seventh-largest holding.
• Natera beat expectations this quarter — EPS $0.35 vs. est. -$0.46 and revenue $665.5M vs. $600.7M — driving upbeat analyst coverage (consensus "Moderate Buy", $253.47 target) and increased institutional buying from firms like JPMorgan and Norges Bank.
• Offsetting the positive operational news, insiders have sold heavily recently (367,669 shares worth roughly $85.6M in the last 90 days, including sales by the CFO and CEO), which may weigh on sentiment.

Pura Vida Investments LLC decreased its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 99.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,500 shares of the medical research company's stock after selling 243,191 shares during the period. Natera makes up approximately 2.6% of Pura Vida Investments LLC's investment portfolio, making the stock its 7th biggest position. Pura Vida Investments LLC's holdings in Natera were worth $402,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. grew its holdings in Natera by 44.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company's stock valued at $1,795,125,000 after buying an additional 3,263,822 shares in the last quarter. Norges Bank bought a new position in shares of Natera during the 2nd quarter valued at approximately $277,749,000. AQR Capital Management LLC grew its holdings in shares of Natera by 44.6% in the second quarter. AQR Capital Management LLC now owns 1,726,750 shares of the medical research company's stock valued at $291,717,000 after purchasing an additional 532,769 shares in the last quarter. Franklin Resources Inc. increased its position in Natera by 20.6% in the second quarter. Franklin Resources Inc. now owns 1,937,647 shares of the medical research company's stock worth $327,346,000 after purchasing an additional 330,696 shares during the last quarter. Finally, Holocene Advisors LP raised its stake in Natera by 118.3% during the second quarter. Holocene Advisors LP now owns 572,832 shares of the medical research company's stock valued at $96,774,000 after purchasing an additional 310,452 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Signatera is being highlighted as a primary growth driver for Natera’s oncology business, supporting revenue momentum and investor optimism about recurring MRD testing demand. Signatera Oncology Test Drives Natera’s (NTRA) Growth
• Positive Sentiment: Management presented at TD Cowen’s healthcare conference; the transcript emphasizes commercial progress across oncology (Signatera), reproductive health and transplant products, reinforcing the narrative behind recent revenue beats. Natera Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Positive Sentiment: Coverage noting why the stock traded up ties the move to the company’s recent operational beats and growth commentary, which can amplify buying interest on upside news. Natera (NTRA) Stock Trades Up, Here Is Why
• Neutral Sentiment: Morgan Stanley trimmed its price target from $265 to $250 but kept an Overweight rating — a modestly negative signal on price scope but still reflects continued analyst confidence. Morgan Stanley Lowers Price Target
• Neutral Sentiment: MarketBeat/analyst notes show a consensus “Moderate Buy” and a cluster of raised targets from other firms, indicating mixed but generally constructive analyst sentiment that could limit downside. NTRA MarketBeat Summary
• Negative Sentiment: Insider selling: CEO Steven Chapman and longtime insider Solomon Moshkevich sold shares in early March (transactions near $200/sh), which can weigh on sentiment even if the trades appear to be routine liquidity. Natera Insider Sells $599,550.00 in Stock

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. TD Cowen reissued a "buy" rating on shares of Natera in a research note on Wednesday, January 7th. Canaccord Genuity Group reiterated a "buy" rating on shares of Natera in a research report on Monday, January 12th. Morgan Stanley decreased their price objective on Natera from $265.00 to $250.00 and set an "overweight" rating on the stock in a research report on Tuesday. BTIG Research raised their price objective on Natera from $230.00 to $260.00 and gave the company a "buy" rating in a research note on Friday, December 5th. Finally, Zacks Research raised Natera from a "strong sell" rating to a "hold" rating in a research report on Thursday, January 1st. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Natera has a consensus rating of "Moderate Buy" and a consensus price target of $253.47.

Insiders Place Their Bets

In related news, CFO Michael Burkes Brophy sold 6,939 shares of Natera stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $227.83, for a total transaction of $1,580,912.37. Following the completion of the sale, the chief financial officer owned 52,120 shares in the company, valued at $11,874,499.60. This trade represents a 11.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 3,950 shares of the company's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $200.02, for a total transaction of $790,079.00. Following the completion of the transaction, the chief executive officer owned 156,607 shares in the company, valued at $31,324,532.14. This represents a 2.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 367,669 shares of company stock worth $85,584,453. 5.63% of the stock is currently owned by company insiders.

Natera Price Performance

Shares of NASDAQ NTRA opened at $203.03 on Thursday. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $256.36. The firm has a 50-day simple moving average of $224.59 and a two-hundred day simple moving average of $204.76. The company has a market cap of $28.78 billion, a P/E ratio of -132.70 and a beta of 1.65.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.81. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.The firm had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. During the same period in the prior year, the business posted ($0.41) earnings per share. As a group, equities research analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.